Joël Rousseau - Publications, H-index & Citations

Back

Joël Rousseau

Université Laval

20H-index

88Paper Count

1.2KCitation Count

Published Papers 34

Publication Date

Prime Editing Mediated Generation and Correction of the mdx5cv Mutation Restores Dystrophin Expression in Myoblasts

International Journal of Molecular Sciences

IF4.9

2026-08-02

OAAI

Ayesha Siddika; Fatima El Husseiny; Joël Rousseau; Jacques P. Tremblay

Save

Molecular characterization of a new R1925X point mutation mouse model for dysferlinopathy

Genes & Diseases

IF9.4

2025-10-20

OAAI

Camille Bouchard; Louis Despax; Joël Rousseau; Jacques P. Tremblay

Save

Universal Prime Editing Therapeutic Strategy for RyR1-Related Myopathies: A Protective Mutation Rescues Leaky RyR1 Channel

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

IF4.9

2025-03-21

OAAI

Godbout, Kelly; Dugas, Mathieu; Reiken, Steven R.; Ramezani, Sina; Falle, Alexia; Rousseau, Joel; Wronska, Anetta E.; Lamothe, Gabriel; Canet, Geoffrey; Lu, Yaoyao; Planel, Emmanuel; Marks, Andrew R.; Tremblay, Jacques P.

Save

Emerging Perspectives on Prime Editor Delivery to the Brain

PHARMACEUTICALS

IF4.8

2024-06-11

OAAI

Bendavid, Eli; Ramezanian, Sina; Lu, Yaoyao; Rousseau, Joel; Schroeder, Avi; Lavertu, Marc; Tremblay, Jacques P.

Save

Decoding the molecular mechanisms related to mutations in the GNAQ/11 and BAP1 genes in ocular melanoma

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Fuentes-Rodriguez, Aurelie; Mitchell, Andrew; Rousseau, Joel; Tremblay, Jacques P.; Landreville, Solange

Save

Successful Correction by Prime Editing of a Mutation in the RYR1 Gene Responsible for a Myopathy

CELLS

IF5.2

2023-12-22

OAAI

Godbout, Kelly; Rousseau, Joel; Tremblay, Jacques P.

Save

Development of a gene therapy treatment for RYR1-related diseases using prime editing

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2023-12-01

PREAI

Godbout, Kelly; Rousseau, Joel; Tremblay, Jacques

Save

Prime editing strategies to mediate exon skipping in DMD gene

FRONTIERS IN MEDICINE

IF3

2023-05-25

OAAI

Mbakam, Cedric Happi; Roustant, Jeanne; Rousseau, Joel; Yameogo, Pouire; Lu, Yaoyao; Bigot, Anne; Mamchaoui, Kamel; Mouly, Vincent; Lamothe, Gabriel; Tremblay, Jacques P.

Save

GNAQ/GNA11 and BAP1 mutant isogenic cell lines engineered by CRISPR/Cas9 gene editing to model ocular melanoma

CANCER RESEARCH

IF16.6

2023-04-04

PREAI

Fuentes-Rodriguez, Aurelie; Mitchell, Andrew; Rousseau, Joel; Tremblay, Jacques P.; Landreville, Solange

Save

Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene

MOLECULAR THERAPY-NUCLEIC ACIDS

IF0

2022-12-01

OAAI

Mbakam, Cedric Happi; Rousseau, Joel; Lu, Yaoyao; Bigot, Anne; Mamchaoui, Kamel; Mouly, Vincent; Tremblay, Jacques P.

Save

Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene

MOLECULAR THERAPY

IF12

2022-07-01

OAAI

Majeau, Nathalie; Fortin-Archambault, Annabelle; Gerard, Catherine; Rousseau, Joel; Yameogo, Pouire; Tremblay, Jacques P.

Save

Insertion of the Icelandic Mutation (A673T) by Prime Editing: A Potential Preventive Treatment for Familial and Sporadic Alzheimer's Disease

CRISPR JOURNAL

IF4

2022-02-01

OAAI

Tremblay, Guillaume; Rousseau, Joel; Mbakam, Cedric Happi; Tremblay, Jacques P.

Save

Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro

MOLECULAR THERAPY-NUCLEIC ACIDS

IF0

2021-06-01

OAAI

Guyon, Antoine; Rousseau, Joel; Begin, Francis-Gabriel; Bertin, Tom; Lamothe, Gabriel; Tremblay, Jacques P.

Save

CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo

MOLECULAR THERAPY

IF12

2018-11-01

OAAI

Duchene, Benjamin L.; Cherif, Khadija; Iyombe-Engembe, Jean-Paul; Guyon, Antoine; Rousseau, Joel; Ouellet, Dominique L.; Barbeau, Xavier; Lague, Patrick; Tremblay, Jacques P.

Save

Increased Frataxin Expression Induced in Friedreich Ataxia Cells by Platinum TALE-VP64s or Platinum TALE-SunTag

MOLECULAR THERAPY-NUCLEIC ACIDS

IF0

2018-09-01

OAAI

Cherif, Khadija; Gerard, Catherine; Rousseau, Joel; Ouellet, Dominique L.; Chapdelaine, Pierre; Tremblay, Jacques P.

Save

Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160

MOLECULAR THERAPY-NUCLEIC ACIDS

IF0

2017-03-01

OAAI

Perrin, Arnaud; Rousseau, Joel; Tremblay, Jacques P.

Save

Characterization of frataxin gene network in Friedreich's ataxia fibroblasts using the RNA-Seq technique

Mitochondrion

IF4.5

2016-09-01

PREAI

Sanchez, Noelia; Chapdelaine, Pierre; Rousseau, Joel; Raymond, Frederic; Corbeil, Jacques; Tremblay, Jacques P.

Save

Deletion of Mutated GAA Repeats from the Intron 1 of the Frataxin Gene Using the CRISPR System Restores the Protein Expression in a Friedreich Ataxia Model

MOLECULAR THERAPY

IF12

2016-05-01

OAAI

Ouellet, Dominique L.; Rousseau, Joel; Cherif, Khadija; Gerard, Catherine; Gilbert, Renald; Garnier, Alain; Gaillet, Bruno; Beausejour, Christian; Tremblay, Jacques P.

Save

CRISPR-Induced Deletion (CinDel) Method Allows Permanent and Efficient Restoration of the DMD Gene Reading Frame in Duchenne Patient Myoblasts and Preserves Truncated Dystrophin Structure

MOLECULAR THERAPY

IF12

2016-05-01

OAAI

Iyombe-Engembe, Jean-Paul; Ouellet, Dominique L.; Barbeau, Xavier; Rousseau, Joel; Chapdelaine, Pierre; Lague, Patrick; Tremblay, Jacques P.

Save

Development of a Therapy for Duchenne Muscular Dystrophy Using Either TALEN of Cas9 Proteins

MOLECULAR THERAPY

IF12

2016-05-01

OAAI

Agudelo, Daniel; Rousseau, Joel; Tremblay, Jacques P.

Save

Research Directions